Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Sales: 2011-2025

Historic Return on Sales for Northwest Biotherapeutics (NWBO) over the last 15 years, with Sep 2025 value amounting to -78.38%.

  • Northwest Biotherapeutics' Return on Sales fell 3473.00% to -78.38% in Q3 2025 from the same period last year, while for Sep 2025 it was -78.38%, marking a year-over-year decrease of 3473.00%. This contributed to the annual value of -53.74% for FY2024, which is 2230.00% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Return on Sales is -78.38%, which was down 16.85% from -67.08% recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Return on Sales high stood at 980.28% for Q3 2022, and its period low was -781.84% during Q2 2022.
  • For the 3-year period, Northwest Biotherapeutics' Return on Sales averaged around -46.76%, with its median value being -43.65% (2024).
  • Per our database at Business Quant, Northwest Biotherapeutics' Return on Sales skyrocketed by 102,708bps in 2022 and then tumbled by 101,088bps in 2023.
  • Over the past 5 years, Northwest Biotherapeutics' Return on Sales (Quarterly) stood at 389.95% in 2021, then plummeted by 43,348bps to -43.52% in 2022, then skyrocketed by 1,208bps to -31.44% in 2023, then plummeted by 2,230bps to -53.74% in 2024, then tumbled by 3,473bps to -78.38% in 2025.
  • Its last three reported values are -78.38% in Q3 2025, -67.08% for Q2 2025, and -51.55% during Q1 2025.